FDA Grants Priority Review to Empliciti Combo Therapy for Relapsed or Refractory Myeloma

The U.S. Food and Drug Administration granted priority review to Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for Empliciti (elotuzumab) combined with Pomalyst (pomalidomide) and…

FDA Approves Darzalex Combo Therapy for Certain Newly Diagnosed Patients

The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with standard therapy for the treatment of patients with newly-diagnosed multiple myeloma who…

Myeloma UK Launches New Clinical Trial to Develop Therapies for High-Risk Myeloma

Myeloma UK has launched a new clinical trial to identify the best treatment options for myeloma patients classified as high-risk. The study is the…